We propose a plausible, unambiguous solution to this enduring puzzle wherein the super-ability (for ApoE2), intermediate ability (for ApoE3) or inability (for ApoE4) to form lipid-protecting intermolecular disulfide bridges is the central molecular determinant accounting for the disparate effects of APOE variants on AD risk in humans. This evidence concerns the gene APOE and Alzheimer disease.